Skip To Main Content
Bart A. van de Wiel on Muck Rack

Bart A. van de Wiel

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bart A.

Contact Bart A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

|
By Georgina V. Long, Kristen Perry, Jurriaan Romano, Serigne Lo, Piyush Grover, Paolo A Ascierto, Rodabe N. Amaria, Tina J. Hieken, Caroline Robert, Lucie Heinzerling, Shahneen Sandhu, Milton Barros, Tara Mitchell, Zeynep Eroglu, Lukas Flatz, Céleste Lebbe, Douglas Johnson, Piotr Rutkowski, Eva Muñoz-Couselo, Omid Hamid, Claudia Trojaniello, Domenico Mallardo, Matthew Block, Dirk Tomsitz, Yang Wang, Andrea Forschner, Matteo S. Carlino, Mathilde Jalving, Michael A. Postow, Ellen Kapiteijn, Karijn P. M. Suijkerbuijk, Laetitia Da Meda, Hannah Burnette, Inderjit Mehmi, Geke A. P. Hospers, Sarah E. Lochrin, Alexander van Akkooi, Hussein Tawbi, Elizabeth M Burton, Michael T Tetzlaff, Robert V. Rawson, Christian Blank, Alexander M. Menzies, Igor V. Samoylenko, Naima Hammoudi, Naima Benannoune, Cigdem Dinckal, Angelina Kuzmenko, P. Francesco Ferrucci, Astrid A. M. van der Veldt, Anna Czarnekca, Bart A. van de Wiel
| Nature Verified
Abstract Neoadjuvant immune checkpoint inhibitors (ICIs) are standard of care for resectable stage IIIB–D melanoma, but knowledge gaps remain regarding optimal treatment type, long-term survival, postsurgical management and clinical, histopathological or molecular subgroups.
Open in Who Shared Issue with article?
See all 1 articles